From: Dilemmas and options for COVID-19 vaccination in children
Type of vaccination | Age group | Number of subjects | Vaccination status | Dosage | Immunogenicity (95% CI) | Detection time interval | Reference |
---|---|---|---|---|---|---|---|
BBIBP-CorV | 3–5 years | 81 | First dose | 2.0 µg | GMT: 14.5 | 28 days | [35] |
83 | 4.0 µg | GMT: 20.2 | |||||
82 | 8.0 µg | GMT: 21.3 | |||||
6–12 years | 84 | 2.0 µg | GMT: 30.0 | ||||
84 | 4.0 µg | GMT: 54.1 | |||||
83 | 8.0 µg | GMT: 55.8 | |||||
13–17 years | 83 | 2.0 µg | GMT: 48.0 | ||||
83 | 4.0 µg | GMT: 61.4 | |||||
82 | 8.0 µg | GMT: 80.2 | |||||
CoronaVac | 3–5 years | 46 | Second dose | 1.5 µg | GMT: 94.1 | 28 days | [32] |
45 | 3.0 µg | GMT: 140.5 | |||||
6–11 years | 69 | 1.5 µg | GMT: 90.3 | ||||
68 | 3.0 µg | GMT: 139.7 | |||||
12–17 years | 71 | 1.5 µg | GMT: 78.3 | ||||
67 | 3.0 µg | GMT: 146.0 | |||||
BNT162b2 | 5–11 years | 264 | Second dose | 10.0 µg | GMT: 1197.6 | 1 month | [53] |
16–25 years | 253 | 30.0 µg | GMT: 1146.5 | ||||
12–15 years | 190 | Second dose | 30.0 µg | GMNT50: 1239.5 | 1 month | [34] | |
16–25 years | 170 | GMNT50: 705.1 | |||||
mRNA-1273 | 6–23 months | 230 | Second dose | 25.0 µg | GMC: 1781 | 28 days | [49] |
2–5 years | 264 | 25.0 µg | GMC: 1410 | ||||
6–11 years | 320 | 50.0 µg | GMPNAT: 1610 | [33] | |||
12–17 years | 340 | 100.0 µg | GMPNAT50: 1401.7 | [50] |